Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate ADAP funding bill to hit floor Sept. 2 as part of Labor/HHS Appropriations bill.

Executive Summary

SENATE ADAP FUNDING BILL TO HIT FLOOR SEPT. 2 as part of the Labor & HHS appropriations bill scheduled for floor consideration following the August Congressional recess. The House Labor/HHS appropriations bill is scheduled to reach the floor the second week of September. The Senate bill (S 1061) allocates $217 mil. for AIDS Drug Assistance Programs, while the House bill (HR 2264) affords ADAPs with $299 mil. While both appropriations are substantially higher than the Clinton Administration's FY 1998 budget request of $167 mil. for the program, the Administration is supporting the higher amount included in the House bill; the ADAP Working Group, composed of AIDS advocacy groups and pharmaceutical companies, predicted in an April report that state ADAPs would need $299 mil. in federal support during fiscal 1998 ("The Pink Sheet" April 21, T&G-5).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts